PIIIW — P3 Health Partners Inc.

Summary of P3 Health Partners Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Fourth Quarter Revenue: $384.8 million, up from $370.7 million in Q4 2024.
• Full Year Revenue: $1.46 billion, down from $1.50 billion in 2024.
• Capitated Revenue PMPM: $1,060 in Q4 2025, a 9% increase from $971 in Q4 2024; full year PMPM was $1,026, a 5% increase from $981 in 2024.
• Adjusted EBITDA: Q4 loss of $76.1 million compared to a loss of $67.6 million in Q4 2024; full year adjusted EBITDA loss of $161.3 million, an improvement from a loss of $167.2 million in 2024.
• Medical Margin: Q4 medical margin was negative $28.7 million; full year medical margin was $23.5 million, down from $85.4 million in 2024.
• Operating Expenses: Q4 operating expenses were $35.1 million, up from $28.7 million in Q4 2024; full year operating expenses decreased to $101.8 million from $111.8 million in 2024.

2. Strategic Updates and Business Highlights

• Geographic Expansion: Announced a partnership to enter a new Medicare Advantage geography, adding 29,000 new members, which will contribute approximately $27 million in revenue for 2026.
• Provider Network Improvements: Over 50% of patients are now served by Tier 1 provider groups, enhancing clinical integration and accountability.
• Quality Performance: Achieved 4-star status across 70% of priority Medicare Advantage plans, which strengthens relationships with payers.
• Operational Improvements: Identified $170 million in structural and operational improvements, focusing on contracting, operational execution, and payer collaboration.

3. Forward Guidance and Outlook

• 2026 Adjusted EBITDA Guidance: Midpoint of $10 million, indicating a potential improvement of up to $170 million from 2025.
• At-Risk Membership: Expected to be between 107,000 and 117,000 members, with total revenue projected between $1.5 billion and $1.7 billion.
• Revenue Drivers: 75% of the projected improvement is already embedded in contracts, with the remainder dependent on operational initiatives and contract renegotiations.

4. Bad News, Challenges, or Points of Concern

• Continued Losses: Despite improvements, the company reported significant losses in adjusted EBITDA and medical margins.
• Operating Expenses Increase: Q4 operating expenses rose due to reclassifications and ongoing costs, indicating potential challenges in cost management.
• Dependency on Execution: Future performance is heavily reliant on the successful execution of operational initiatives and contract renegotiations, which may pose risks if not achieved.

5. Notable Q&A Insights

• Clarification on Membership Numbers: The 112,000 at-risk members do not include the additional 29,000 from the Nebraska agreement.
• Glidepath to Risk: The new Nebraska partnership includes a two-year glidepath to risk with performance metrics that must be met.
• Contractual Changes: Improved contracts with payers include adjustments based on Stars performance and premium rates, reflecting a more collaborative approach to align incentives.

Overall, P3 Health Partners is positioning itself for growth in 2026 with a focus on operational improvements and strategic partnerships, despite facing challenges related to ongoing losses and the need for effective execution of its plans.